Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI

被引:107
作者
Noworolski, SM [1 ]
Henry, RG [1 ]
Vigneron, DB [1 ]
Kurhanewicz, J [1 ]
机构
[1] Univ Calif San Francisco, Ctr Mol & Funct Imaging, Dept Radiol, Ctr Sci, San Francisco, CA 94143 USA
关键词
prostate; dynamic contrast-enhanced MRI; cancer; benign prostatic hyperplasia; motion;
D O I
10.1002/mrm.20374
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study characterized dynamic contrast-enhanced (DCE) MRI of prostate tissues: cancerous peripheral zone (PZ), normal PZ, stromal benign prostatic hyperplasia (BPH), and glandular BPH. MRI, MRSI, and DCE MRI were performed on 25 patients. Tissues were identified with MRI, MRSI, and (when available) biopsy results. Motion between MRI and DCE MRI, and within DCE MRI was assessed and manually corrected. To assess tissue and patient effects, native T-1's were measured in 12 of 25 patients, and DCE MRI results were normalized to muscle enhancement. Regions of cancer had a higher peak enhancement (P < 0.006), faster enhancement rate (P < 0.0008), and faster washout slope (P < 0.05) than normal PZ tissues. Stromal BPH had the fastest enhancement rate (P < 0.003) of all tissues and tended to have the greatest enhancement. Intersequence motion averaged 2.6 mm and reached 7.9 mm. Motion within DCE MRI was generally minimal (< 2 pixels), but one case showed a large shift that would have confounded the results. Native T-1's were similar across the prostatic tissues. Interpatient variability in DCE MRI was only partially reduced by normalization to muscle. DCE MRI of the prostate discriminated PZ cancer from normal PZ tissues and predominantly stromal and glandular BPH. (C) 2005 Wiley-Liss, Inc.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 28 条
  • [1] Barentsz JO, 1999, J MAGN RESON IMAGING, V10, P295, DOI 10.1002/(SICI)1522-2586(199909)10:3<295::AID-JMRI10>3.0.CO
  • [2] 2-Z
  • [3] BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO
  • [4] 2-6
  • [5] Prostate cancer tumor volume: Measurement with endorectal MR and MR spectroscopic imaging
    Coakley, FV
    Kurhanewicz, J
    Lu, Y
    Jones, KD
    Swanson, MG
    Chang, SD
    Carroll, PR
    Hricak, H
    [J]. RADIOLOGY, 2002, 223 (01) : 91 - 97
  • [6] Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis
    Galbraith, SM
    Lodge, MA
    Taylor, NJ
    Rustin, GJS
    Bentzen, S
    Stirling, JJ
    Padhani, AR
    [J]. NMR IN BIOMEDICINE, 2002, 15 (02) : 132 - 142
  • [7] A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer
    Holmberg, L
    Bill-Axelson, A
    Helgesen, F
    Salo, JO
    Folmerz, P
    Häggman, M
    Andersson, S
    Spångberg, A
    Busch, C
    Nordling, S
    Palmgren, J
    Adami, HO
    Johansson, J
    Norlén, BJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (11) : 781 - 789
  • [8] Local staging of prostate cancer with endorectal MR imaging: Correlation with histopathology
    Jager, GJ
    Ruijter, ETG
    vandeKaa, CA
    delaRosette, JJMCH
    Oosterhof, GON
    Thornbury, JR
    Barentsz, JO
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 166 (04) : 845 - 852
  • [9] Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: Correlation with histopathologic results
    Jager, GJ
    Ruijter, ETG
    vanderKaa, CA
    delaRosette, JJMCH
    Oosterhof, GON
    Thornbury, JR
    Ruijs, SHJ
    Barentsz, JO
    [J]. RADIOLOGY, 1997, 203 (03) : 645 - 652
  • [10] Pre-treatment staging of prostate cancer: recent advances and future prospects
    Kirby, RS
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 1997, 1 (01) : 2 - 10